Total Revenue

19% decline (from $234,058 to $189,121)

Total Revenue declined by 19% YoY in Q4 2024 primarily due to intensified competition in the cannabis telemedicine market—a trend that had already impacted revenue in previous periods (e.g., Q3 2024 saw a 27% decline due to similar competitive pressures). " " "

Gross Profit

26% decline (from $161,793 to $118,872)

Gross Profit fell by 26% YoY as a direct outcome of the revenue drop; despite attempts to manage costs and modestly improve margins, the reduced volume led to a significant decline in gross profit, echoing earlier Q3 trends where revenue shrinkage outpaced cost reductions. " " " "

Operating Expenses

21% decrease (from $378,943 to $300,719)

The reduction in Operating Expenses of 21% YoY reflects ongoing cost-cutting initiatives, including aggressive reductions in depreciation and amortization, wages, and general administrative expenses that were also prominently observed in previous periods (e.g., a 41% decrease in Q3 2024 driven by similar measures). " " " "

Net Loss

26% reduction (from ($327,808) to ($241,110))

Net Loss improved by 26% YoY, as the impact of lower revenue was partly offset by significant reductions in operating expenses. This improvement mirrors earlier periods where cost-cutting efforts helped narrow losses despite declining revenue, indicating a continued focus on operational leverage. " "

Cash Balance

Nearly 50% drop (from $83,762 to $41,352)

The Cash Balance dropped by almost 50% YoY, driven by substantial cash outflows for operating activities and reduced investments in equity securities—a continuation of liquidity challenges seen in prior periods where cash usage was markedly high. " "

Total Assets

Approximately 5% decline (from $2,020,554 to $1,918,135)

Total Assets saw a modest decline of roughly 5% YoY, primarily due to lower cash levels, reductions in the fair value of investments, and the ongoing amortization of intangible assets—a reflection of the cumulative asset shrinkage trends that began in previous periods. " "